

CIPR JC109
SEP 11 2003
U.S. PATENT AND TRADEMARK OFFICE

Serial No. 60/599/646,778
Amtd. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Listing of Claims:

Claim 1 (Original) A nucleic acid sequence that codes a gene product or a part thereof, comprising

- a) a nucleic acid sequence, selected from the group Seq. ID Nos. 1-10, 12, 13, 15, 16, 18-36, 38-57 and 258-273
- b) an allelic variation of the nucleic acid sequences named under a)
- or
- c) a nucleic acid sequence that is complementary to the nucleic acid sequences named under a) or b).

RECEIVED

SEP 15 2003

Claim 2 (Cancel)

TECH CENTER 1600/2900

Claim 3 (Cancel)

Claim 4 (Original) Nucleic acid sequence Seq. ID Nos. 27, 32, 42, 46, 67, 76, 78, 80, 85, 88, 90, 108 and 112, wherein they are also expressed elevated in breast tumor tissue.

§Appl. No. 09/646,778
Amdt. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Claim 5 (Previously presented) BAC, PAC and Cosmid clones containing functional genes and their chromosomal localization according to sequences Seq. ID. Nos. 1-10, 12, 13, 15, 16, 18-36, 38-57, and 258-273 of Claim 3 for use as vehicles fro gene transfer.

Claim 6 (Previously presented) A nucleic acid sequence according to Claim 3, wherein it has 90% homology to a human nucleic acid sequence.

Claim 7 (Previously presented) A nucleic acid sequence according to Claim 3, wherein it has 95% homology to a human nucleic acid sequence.

Claim 8 (Previously presented) A nucleic acid sequence comprising a portion of the nucleic acid sequences named in claim 3, in such a sufficient amount that they hybridize with the sequences according to claim 3 or a sequence having 90% homology thereto.

Claim 9 (Previously presented) A nucleic acid sequence according to Claim 3, wherein the size of the fragment has a length of at least 50 to 4500 bp.

Claim 10 (Previously presented) A nucleic acid sequence according to Claim 3, wherein the size of the fragment has a length of at least 50 to 4000 bp.

Claim 11 (Previously presented) A nucleic acid sequence according to Claim 3, which codes at least one partial sequence of a bioactive polypeptide.

Claim 12 (Previously presented) An expression cassette, comprising a nucleic acid fragment or a sequence according to Claim3, together with at lest one control or regulatory sequence.

§Appl. No. 09/646,778
Amdt. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Claim 13 (Original) An expression cassette, comprising a nucleic acid fragment or a sequence according to claim 11, in which the control or regulatory sequence is a suitable promoter.

Claim 14 (Previously presented) An expression cassette according to Claim 12, wherein the DNA sequences located on the cassette code a fusion protein, which comprises a known protein and a bioactive polypeptide fragment.

Claim 15 (Previously presented) Use of nucleic acid sequences according to Claim 3 for producing full-length genes.

Claim 16 (Original) A DNA fragment, comprising a gene, that can be obtained from the use according to claim 15.

Claim 17 (Previously presented) Host cell, containing as the heterologous part of its expressible genetic information a nucleic acid fragment according to Claim 3.

Claim 18 (Original) Host cell according to claim 17, wherein it is a prokaryotic or eukaryotic cell system.

Claim 19 (Previously presented) Host cell according to Claim 17, wherein the prokaryotic cell system is E. coli and the eukaryotic cell system is an animal, human or yeast cell system.

Claim 20 (Previously presented) A process for producing a polypeptide or a fragment, wherein the host cells according to Claim 17 are cultivated.

§Appl. No. 09/646,778
Amdt. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Claim 21 (Original) An antibody that is directed against a polypeptide or a fragment that is coded by the nucleic acids of sequences Seq. ID. Nos. 124-257 and 274-307, which can be obtained according to claim 20.

Claim 22 (Original) An antibody according to claim 20, wherein it is monoclonal.

Claim 23 (Original) An antibody according to claim 20, wherein it is a phage display antibody.

Claim 24 (Currently Amended) ~~Polypeptide partial sequences according to sequences Seq. ID Nos. An isolated polypeptide comprising an amino acid sequence selected from the sequences set forth in SEQ ID NOS: 124-257 and 274-307.~~

Claim 25 (Canceled)

Claim 26 (Original) Polypeptide partial sequences according to claim 22, with at least 90% homology to these sequences.

Claim 27 (Currently Amended) ~~A An isolated polypeptide identified using that is developed from a phage display technology and that is capable of binding can bind to the polypeptide of partial sequences according to claim 24.~~

Claim 28 (Original) Use of polypeptide partial sequences according to claim 24 in a phage display process.

Claim 29 (Original) Use of nucleic acid sequences according to claim 3 in a phage display process.

§Appl. No. 09/646,778
Amdt. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Claim 30 (Cancel)

Claim 31 (Previously presented) Use of nucleic acid sequences according to sequences Seq. ID Nos. 1-123 and 258-273 of Claim 3 for expression of polypeptides that can be used as tools for finding active ingredients against ovarian cancer.

Claim 32 (Previously presented) Use of nucleic acid sequences Seq. ID Nos. 1-123 and 258-273 of Claim 3 in sense or antisense form.

Claim 33 (Previously presented) Use of polypeptide partial sequences Seq. ID Nos. 124-257 and 274-307 as pharmaceutical agents of Claim 35 in gene therapy for treatment of ovarian cancer.

Claim 34 (Previously presented) Use of polypeptide partial sequences Seq. ID Nos. 124-257 and 247-307 for the production of a pharmaceutical agent of Claim 35 for treatment of ovarian cancer.

Claim 35 (Currently Amended) A pharmaceutical composition comprising Pharmaceutical agent, containing at least one polypeptide comprising an amino acid selected from SEQ ID NOS: 124-257 and 274-307.

Claim 36 (Previously presented) A nucleic acid sequence according to Claim 3, wherein it is a genomic sequence.

§Appl. No. 09/646,778
Amdt. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Claim 37 (Previously presented) A nucleic acid sequence according to Claim 3, wherein it is an mRNA sequence.

Claim 38 (Previously presented) Genomic genes, their promoters, enhancers, silencers, exon structure, intron structure and their splice variants, that can be obtained from cDNAs of sequences Seq. ID Nos. 1-123 and 258-273 of Claim 3.

Claim 39 (Original) Use of the genomic genes according to claim 36, together with suitable regulatory elements.

Claim 40 (Previously presented) Use according to claim 39, wherein the regulatory element is a suitable promoter and/or enhancer.

Claim 41 (Original) A nucleic acid sequence according to Claim 3, wherein the size of the fragment has a length of at least 300 to 3500 bp.

Claim 42 (New) An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 288.

Claim 43 (New) An isolated polypeptide consisting of the amino acid sequence of claim 42.

Claim 44 (New) An isolated polypeptide comprising an amino acid sequence having at least 90% sequence homology to the amino acid sequence as set forth in SEQ ID NO: 288.

Claim 45 (New) An isolated polypeptide of claim 44 which is human.

§Appl. No. 09/646,778
Amdt. dated September 11, 2003
Reply to Office Action of, March 11, 2003

Claim 46 (New) An isolated polypeptide consisting of the amino acid sequence of claim 44.

Claim 47 (New) An isolated polypeptide of claim 46 which is human.

Claim 48 (New) An isolated polypeptide of claim 42 which is human.

Claim 49 (New) An isolated polypeptide of claim 44 which is overexpressed in ovarian tissue.

Claim 50 (New) An isolated polypeptide of claim 45 which is overexpressed in ovarian tissue

Claim 51 (New) An isolated polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 288, or a specific fragment thereof.